Clinical trials: Cardiovascular Condition
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
- Trial name
- SAPPHIRE (NCT02980874)
- Testing
- suprachoroidal CLS-TA, IVT aflibercept
- Where
- 110 sites in United States, Australia and 14 more
- Volunteers
- 460 people
- Sponsor
- Clearside Biomedical, Inc.
Hypertension
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
The purpose of this study is to compare the efficacy and safety of TAK-491 (azilsartan medoxomil), once daily (QD), to valsartan in participants with essential hypertension.
- Trial name
- NCT00591578
- Testing
- Azilsartan Medoxomil, Valsartan
- Where
- 88 sites in United States, Chile and 2 more
- Volunteers
- 984 people
- Sponsor
- Takeda
Hypertension Associated, Type II Diabetes Mellitus
Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
The purpose of this study is to evaluate the efficacy and safety of Egito association in the treatment of type 2 diabetes mellitus and hypertension
- Trial name
- EGITO (NCT04970108)
- Testing
- Egito, Empagliflozin + telmisartan
- Sponsor
- EMS
Heart Failure
Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration
The purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.
- Trial name
- FUROPHARM-HF (NCT02350725)
- Testing
- Furosemide injection solution for subcutaneous administration (80 mg), Oral Furosemide tablets (80 mg)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- scPharmaceuticals, Inc.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Hungary Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES)
- Trial name
- NCT01892917
- Where
- 13 sites in Hungary
- Volunteers
- 2,000 people
- Sponsor
- Biotronik Hungária Kft.
Hypertension, Cardiac Arrhythmias
Clinical Trial in Patients With Hypertension and Left Ventricular Dysfunction
Arterial hypertension causes adverse effects on the entire cardiovascular system, with effects centrally such as diastolic dysfunction and structural changes of the left ventricle and, peripherally such as endothelial dysfunction…
- Conditions
- Hypertension, Cardiac Arrhythmias, Diabetes Mellitus, Renal Insufficiency
- Trial name
- NCT02148991
- Where
- 2 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Coronary Arterioscleroses
EucaLimus Post-Market Registry
To collect post marketing surveillance data on consecutive patients with coronary heart disease intended to be or treated by the Eucalimus sirolimus eluting PTCA stent when used according to the Instructions for Use.
- Trial name
- NCT06621524
- Testing
- EucaLimus coronary stent system
- Where
- 10 sites in Czechia, Malaysia and 1 more
- Volunteers
- 251 people
- Sponsor
- OrbusNeich
Diabetes Mellitus, Type 2, Hypertension
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of…
- Trial name
- NCT01370005
- Testing
- BI 10773
- Where
- 120 sites in United States, Canada and 10 more
- Volunteers
- 825 people
- Sponsor
- Boehringer Ingelheim
Aortic Aneurysm, Abdominal
Endurant Stent Graft System Post Approval Study (ENGAGE PAS)
The purpose of the study is to demonstrate the long term safety and effectiveness of the Endurant Stent Graft System for the endovascular treatment of infrarenal abdominal aortic aneurysms in a post-approval environment, through…
- Trial name
- NCT01379222
- Testing
- Endurant Stent Graft System
- Where
- 24 sites in United States
- Volunteers
- 178 people
- Sponsor
- Medtronic Cardiovascular
Pulmonary Embolism
SaExten Vena Cava Filter System in Prevention of Pulmonary Embolism
The purpose of this study is to evaluate the efficacy and safety of SaExten vena cava filter (VCF) system (ShenZhen KYD BioTech Co., Ltd., China) in prevention of pulmonary embolism (PE).
- Trial name
- NCT04948502
- Testing
- SaExten vena cava filter system, Denali inferior vena cava filter
- Where
- 16 sites in China
- Volunteers
- 192 people
- Sponsor
- ShenZhen KYD Biomedical Technology Co., Ltd.
Diabetes Mellitus, Hypertension
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
- Trial name
- NCT05970237
- Where
- South Korea
- Volunteers
- 9,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, arsenic trioxide, and ascorbic acid, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Trial name
- NCT00085345
- Testing
- arsenic trioxide, ascorbic acid, melphalan
- Where
- 19 sites in United States
- Sponsor
- Oncotherapeutics
Fabry Disease
This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.
This study is designed to evaluate safety and PK/PD in Canadian Fabry patients.
- Trial name
- NCT01304277
- Testing
- agalsidase alfa
- Where
- 5 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Shire
Congestive Heart Failure
Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
The purpose of this study is to evaluate the effects of oral lixivaptan capsules in patients with congestive heart failure.
- Trial name
- NCT01055912
- Testing
- Lixivaptan
- Where
- 25 sites in United States
- Volunteers
- 170 people
- Sponsor
- CardioKine Inc.
Diabetic Foot Ulcer
Bioburden Reduction of Diabetic Foot Ulcer
Study to see if a laser can get rid of bacateria called MRSA in your diabetic ulcer
- Trial name
- NCT00776854
- Testing
- Noveon laser
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nomir Medical Technologies
Hypertension
The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects
This study is a single-center, randomized, open, double-cycle and double-cross and self-reflection phase Ic clinical trial, to evaluate effect and safety of high fat diet on pharmacokinetics of SPH3127 tablets.
- Trial name
- NCT03249753
- Testing
- SPH3127 200mg Panel A, SPH3127 200mg Panel B
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Pneumothorax, Pulmonary Nodule, Solitary
Multi-Reader Retrospective Study Examining Carebot AI CXR 2.0.21-v2.01 Implementation in Everyday Radiology Clinical Practice
The primary objective is to evaluate the performance parameters of the proposed DLAD (Carebot AI CXR) in comparison to individual radiologists.
- Conditions
- Pneumothorax, Pulmonary Nodule, Solitary, Atelectasis, Subcutaneous Emphysema
- Trial name
- NCT05963945
- Testing
- Carebot AI CXR
- Where
- Czechia
- Volunteers
- 956 people
- Sponsor
- Carebot s.r.o.
Hypertension
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses.
- Trial name
- NCT01150357
- Testing
- Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
- Trial name
- NCT06991257
- Testing
- Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
- Where
- 150 sites in United States, Argentina and 12 more
- Volunteers
- 620 people
- Sponsor
- Pfizer
Multiple Myeloma
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
This is a phase 2, multicenter, open label, nonrandomized study for patients with MM who will receive treatment with a SC bortezomib-containing combination regimen that does not contain thalidomide or vincristine.
- Trial name
- NCT01695330
- Testing
- Subcutaneous bortezomib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oncotherapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.